News & Views
Collaboration to Investigate IBD Candidates
Jun 28 2017
Numab Therapeutics AG (Numab) has announced a collaboration and option agreement with Kaken Pharmaceutical for the identification of a multispecific antibody candidate for development in
inflammatory disease. Under the agreement, Kaken, a Japanese company with strong experience in developing and commercialising novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery will obtain an option to conclude a license and co-development agreement after identification of lead candidate generated by Numab using its multispecific antibody technology platform. Kaken is to fully fund the research program. Further financial details are not disclosed.
Founded in 2011, Numab develops a proprietary pipeline of multi specific biotherapeutics in immunooncology and immunology and has a numberof discovery partnerships with pharmaceutical companies. The company is represented in Japan by PharmaBDL
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Apr 25 2024 Istanbul, Turkey
Apr 28 2024 Montreal, Quebec, Canada
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA